ARO-INHBE + tirzepatide

ARO-INHBE + tirzepatide is an investigational **combination therapy** for obesity and metabolic diseases, currently in Phase 1/2a clinical trials. **ARO-INHBE** is a small interfering RNA (siRNA) drug designed to reduce hepatic expression of the **INHBE gene** and its secreted product **Activin E**, with the aim of improving fat distribution, boosting lipolysis, reducing visceral adiposity, and preserving lean muscle mass. **Tirzepatide** is a dual **GLP-1/GIP receptor co-agonist** approved for type 2 diabetes and weight management, which acts through incretin hormone modulation to reduce blood glucose and body weight. The combination seeks additive or synergistic efficacy in reducing body weight and fat mass while addressing muscle preservation limitations of current obesity therapies. The developer and trial sponsor is **Arrowhead Pharmaceuticals**. The combination is being evaluated in both diabetic and non-diabetic obese adults, with tirzepatide administered subcutaneously and ARO-INHBE delivered systemically as an siRNA agent targeting hepatic INHBE.